

**THE GARY KELLY (DROGHEDA) CANCER SUPPORT CENTRE
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

	2024	2023
	€	€
Income	592,050	438,248
Administrative expenses	(637,138)	(521,382)
Other operating income	99,515	47,318
	<hr/>	<hr/>
Operating surplus/(deficit)	54,427	(35,816)
Interest receivable and similar income	16,958	635
	<hr/>	<hr/>
Surplus/(deficit) before taxation	71,385	(35,181)
Tax on surplus/(deficit)	-	-
	<hr/>	<hr/>
Surplus/(deficit) for the financial year	71,385	(35,181)

THE GARY KELLY (DROGHEDA) CANCER SUPPORT CENTRE COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

BALANCE SHEET AS AT 31 DECEMBER 2024

	Notes	2024 €	€	2023 €	€
Fixed assets					
Tangible assets	3		870,203		903,271
Current assets					
Debtors	4	18,120		3,027	
Cash at bank and in hand		1,380,537		1,274,709	
		<u>1,398,657</u>		<u>1,277,736</u>	
Creditors: amounts falling due within one year	5	(44,964)		(24,496)	
Net current assets			1,353,693		1,253,240
Total assets less current liabilities			<u>2,223,896</u>		<u>2,156,511</u>
Creditors: amounts falling due after more than one year	6		(116,000)		(120,000)
Net assets			<u>2,107,896</u>		<u>2,036,511</u>
Reserves					
Income and expenditure account			<u>2,107,896</u>		<u>2,036,511</u>

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Statement 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 23 May 2025 and are signed on its behalf by:

Barbara Kelly
Director

David Gordon
Director